

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : A61K 31/27, 31/66</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/32103 (43) International Publication Date: 17 October 1996 (17.10.96)</p>
<p>(21) International Application Number: PCT/US96/04953 (22) International Filing Date: 11 April 1996 (11.04.96) (30) Priority Data: 08/420,935 12 April 1995 (12.04.95) US (71) Applicant: THE PROCTER &amp; GAMBLE COMPANY [US/US]; One Procter &amp; Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventor: CAMDEN, James, Berger; 7339 Charter Cup Lane, West Chester, OH 45069 (US). (74) Agents: REED, T., David et al.; The Procter &amp; Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES, N-CHLOROPHENYLTHIOCARBAMATES AND N-PHOSPHONOGLYCINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCERS AND VIRUSES IN MAMMALS</p> <p>(57) Abstract</p> <p>This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a 10:1 to 1:10 mixture of (1) N-chlorophenylcarbamates and N-chlorophenylthiocarbamates and (2) N-phosphonoglycine derivatives which are systemic herbicides. This composition can also be used to treat viral infections.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES, N-CHLOROPHENYLTHIOCARBAMATES AND N-PHOSPHONOGLYCINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCERS AND VIRUSES IN MAMMALS

TECHNICAL FIELD

This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a mixture of (1) N-chlorophenyl carbamates and N-chlorophenylthiocarbamates and (2) N-phosphonoglycine derivatives which are systemic herbicides. This composition can also be used to treat viral infections.

BACKGROUND OF THE INVENTION

Cancers are the leading cause of death in animals and humans. The exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.

Many types of chemotherapeutic agents have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells. The exact mechanism for the action of these chemotherapeutic agents are not always known.

Despite advances in the field of cancer treatment the leading therapies to date are surgery, radiation and chemotherapy. Chemotherapeutic approaches are said to fight cancers that are metastasized or ones that are particularly aggressive. Such cytotoxic or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing. To date, hormones, in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylating agents, and anti-metabolites form the bulk of therapies available to oncologists. Ideally cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable. Unfortunately, none have been found and instead agents which target especially rapidly dividing cells (both tumor and normal) have been used.

Clearly, the development of materials that would target tumor cells due to some unique specificity for them would be a breakthrough. Alternatively, materials

that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable.

Therefore, it is an object of this invention to provide a pharmaceutical composition that is effective in inhibiting the growth of tumors and cancers in mammals with mild or no effects on normal cells.

More specifically, it is an object of this invention to provide an anti-cancer composition comprising a pharmaceutical carrier and a N-chlorophenylcarbamate or N-chlorophenylthiocarbamate derivative in combination with a N-phosphonoglycine derivatives as defined herein, along with a method of treating such cancers.

These compositions are also effective against viruses. Therefore it is a further object of this invention to provide a composition for and a method of treating viral infections such as herpes, HIV, influenza and rhinoviruses.


These and other objects will become evident from the following detailed description of this inventions.

15


#### SUMMARY OF THE INVENTION

A pharmaceutical composition for treatment of mammals, and in particular, warm blooded animals and humans, comprising a pharmaceutical carrier and an effective amount anti-cancer compound selected from the group consisting of a mixture of (1) N-phosphonoglycine derivatives of the formula:

20



wherein X is selected from the group consisting of hydroxy, alkoxy or chloroxy up to 12 carbon atoms; lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetates, salicylates, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline; and (2) N-chlorophenyl-carbamates and N-chlorophenylthiocarbamates of the formula:



wherein X is oxygen or sulfur; n is from 1 to 3; R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl, and the pharmaceutical acceptable organic and inorganic acid salts thereof.

These compositions can be used to inhibit the growth of cancers and other malignant tumors in humans or animals by administration of an effective amount of the N-phosphonoglycine derivatives and the N-chlorophenyl carbamates and N-chlorophenylthiocarbamates either orally, rectally, topically or parenterally, intravenously, or by direct injection near or into the tumor. These compositions are effective in killing or slowing the growth of tumors, yet are safer than adriamycin on normal, healthy cells.

These compositions are also effective against viruses, such as HIV, herpes, influenza and the like.

#### DETAILED DESCRIPTION OF THE INVENTION

##### A. Definitions:

As used herein, the term "comprising" means various components can be conjointly employed in the pharmaceutical composition of this invention. Accordingly, the terms "consisting essentially of" and "consisting of" are embodied in the term comprising.

As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.

As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.

As used herein, a "pharmaceutical addition salts" includes a pharmaceutically acceptable salt of the anti-cancer compound. These include acid salts of the amines and alkali or alkaline earth metal salt of the carboxylic acids.

As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.


As used herein, "cancer" refers to all types of cancers or neoplasm or tumors found in mammals.

As used herein, the "anti-cancer compounds" are N-phosphonoglycines in combination with N-chlorophenylcarbamates and N-chlorophenylthiocarbamates.

As used herein, "viruses" include viruses which cause disease (viral infections) in warm blooded mammals, e.g., HIV, herpes, influenza, rhinoviruses, and the like.

## 15 B. THE ANTI-CANCER COMPOUNDS

The anti-cancer compounds are a combination of (1) N-phosphonoglycines and (2) N-chlorophenylcarbamates and N-chlorophenylthio carbamates which are known for their herbicidal activities. They are systemic herbicides used to prevent and eradicate certain plants or weeds or to regulate plant growth. The carbamates have the following structure




wherein n is from 1 to 3; R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, and X is sulfur or oxygen; and the pharmaceutical addition salts of these compounds.

Preferred compounds are those in which R is alkyl with 1 to 4 carbons, preferably, isopropyl and X is oxygen.

These compounds are prepared by the methods described in US. 2,695,225 issues to Witman (1954) and in U.S. 2,734,911 issued to Strain (1956).

The N-phosphonoglycines have the formula:



wherein X is selected from the group consisting of hydroxy, alkoxy or chloroxy up to 12 carbon atoms; lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline.

The N-phosphonoglycine compounds are prepared according to the method found in U.S. 3,799,758 issued to Franz (1974).

The mixture of the (1) N-phosphonoglycines and (2) the N-chlorophenylcarbamates and the N-chlorophenylthiocarbamates compounds is in a ratio of 10:1 to about 1:10 relative to each other on a mole weight basis. Preferably a ratio of 5:1 to 1:5 is used, and most preferred a 1:1 mixture.

#### C. DOSAGE

Any suitable dosage may be given in the method of the invention. The type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor being treated. Generally a dosage of between about 2 milligrams (mg) per kilogram (kg) of body weight and about 400 mg per kg of body weight is suitable. Preferably from 15 mg to about 150 mg/kg of body weight is used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. The dosage unit can also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical or parenteral administration or intravenous injection or by injection into or around the tumor site.



#### D. DOSAGE DELIVERY FORMS

The anti-cancer compounds are typically mixed with a pharmaceutically acceptable carrier. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. The active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include aqueous solutions, solutions or suspensions in water, pharmaceutically acceptable fats or oils, alcohols or other organic solvents, including esters, elixirs, syrups, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, and melting agents. Oral dosage forms would contain flavorants and coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.

Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in US. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976).

#### E. METHOD OF TREATMENT

The method of treatment can be any suitable method which is effective in the treatment of the particular virus, cancer or tumor type that is being treated. Treatment may be oral, rectal, topical, parenteral, intravenous or injection into or around the tumor site and the like. The method of applying an effective amount also varies depending on the tumor being treated. It is believed that parenteral treatment by intravenous or subcutaneous, or intramuscular application, formulated with an appropriate carrier, additional cancer inhibiting compound or compounds or diluent to facilitate application will be the preferred method of administering the compounds to warm blooded animals.

The method of treating viral infections may also be by oral, rectal, parenteral, topical or intravenous administration. The actual time and dose administration is dependent on the type of viral infection, the type of administration and the blood level desired.

The following examples are illustrative and are not meant to be limiting to the invention.

##### Colon, Breast and Lung Tumor Cells Test

The following cell culture tests were performed to test the toxicity of N-chlorophenylcarbarnates and N-chlorophenylthiocarbarnates compounds on colon, breast and lung human tumor cells. The viability of the cells were tested by looking at MTT (3-[4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide) reduction. MTT assay is a well known measure of cell viability.

The colon tumor cells (HT29 from American Type Culture Collection (ATCC) ) and the breast cells (MX1 from cell lines from ATCC) were cultured in Eagle's Miminal Essential Medium with 10% fetal bovine serum. The lung tumor cells (A549 from ATCC cell lines) were cultured in Ham's F12 medium with 10% fetal bovine serum.

The tumor cells were passaged and seeded into culture flasks at the desired cell densities. The culture medium was decanted and the cell sheets were washed twice with phosphate buffered saline (PBS). The cells were trypsinized and triturated prior to seeding the flasks. Unless otherwise indicated the cultures were incubated at  $37 \pm 1^\circ \text{C}$  in a humidified atmosphere of  $5 \pm 1\%$  carbon dioxide in air. The cultures were incubated until they were 50-80% confluent.

The cells were subcultured when the flasks were subconfluent. The medium was aspirated from the flasks and the cell sheets rinsed twice with PBS. Next, the Trypsin Solution was added to each flask to cover the cell sheet. The Trypsin Solution was removed after 30-60 seconds and the flasks were incubated at room temperature

for two to six minutes. When 90% of the cells became dislodged, growth medium was added. The cells were removed by trituration and transferred to a sterile centrifuge tube. The concentration of cells in the suspension was determined, and an appropriate dilution was made to obtain a density of 5000 cells/ml. The cells were subcultured  
5 into the designated wells of the 96-well bioassay plates (200 microliter cell suspension per well). PBS was added to all the remaining wells to maintain humidity. The plates were then incubated overnight before test article treatment.

Each dose of test article was tested by treating quadruplicate wells of cultures with 100 microliter of each dilution. Those wells designated as solvent controls  
10 received an additional 100 microliter of methanol control; negative controls wells received an additional 100 microliters of treatment medium. PBS was added to the remaining wells not treated with test article or medium. The plates were then incubated for approximately 5 days.

At the end of the 5 day incubation, each dose group was examined  
15 microscopically to assess toxicity. A 0.5 mg/ml dilution of MTT was made in treatment medium, and the dilution was filtered through a 0.45 micrometer filter to remove undissolved crystals. The medium was decanted from the wells of the bioassay plates. Immediately thereafter, 2000 microliter of the filtered MTT solution was added to all test wells except for the two untreated blank test wells. The two blank wells  
20 received 200 microliters of treatment medium. The plates were returned to the incubator for about 3 hours. After incubation, the MTT containing medium was decanted. Excess medium was added to each well and the plates were shaken at room temperature for about 2 hours.

The absorbance at 550 nm (OD<sub>550</sub>) of each well was measured with a  
25 Molecular Devices (Menlo Park, CA) VMax plate reader.

The mean OD<sub>550</sub> of the solvent control wells and that of each test article dilution, and that of each of the blank wells and the positive control were calculated. The mean OD<sub>550</sub> of the blank wells was subtracted from the mean of the solvent control wells and test article wells, respectively, to give the corresponding mean  
30 OD<sub>550</sub>.

$$\% \text{ of Control} = \frac{\text{corrected mean OD}_{550} \text{ of Test Article Dilution}}{\text{corrected mean of OD}_{550} \text{ of Solvent Control}} \times 100$$

Dose response curves were prepared as semi-log plots with % of control on the ordinate (linear) and the test article concentration on the abscissa (logarithmic).  
35 The EC<sub>50</sub> was interpolated from the plots for each test article.

For the test articles administered in methanol, separate responses were prepared to correct for the methanol data.

Adriamycin was used as a positive control. In all cases, it was more toxic than any of the test materials by one or two logs. Adriamycin is one of the more potent agents in current use and one with significant side effects. The peak plasma concentration of other, quite effective chemotherapeutic agents may be 10 to 50 times higher than that of Adriamycin. The EC-50 is the concentration at which one half the cells are killed.

Table 1

Test Material	EC-50 Result (ppm)					
	HT29	HT29	MX1	MX1	A549	A549
Adriamycin	0.003	0.006	0.02	0.001	0.03	0.009
chloroprofam®	13.3	11.4	91.8	108	12.6	92.5
glyphosate	5.41	3.73	36.5	14.6	25.9	22.3
1:1 mixture*	1.96	1.61	9.70	8.78	10.8	10.1

\* a mixture of chloroprofam® and glyphosate®.

In normal healthy cells, the following results were obtained:

Table 2

Test Material	EC-50					
	Broncheal Cells Fibroblasts		Keratinocyte Cells			
chloroprofam®	0.002	>15.2	3.9	13.0	>152	64.2
glyphosate	1.59	3.54	3.09	3.21	86.1	35.8
1:1 mixture*	0.001	0.497	0.242	0.286	129	5.95
Adriamycin	0.015	0.0020	0.0035	0.0093	0.065	0.10

\* a mixture of chloroprofam® and glyphosate®


These experiments show that these compositions are effective in killing tumor cells without significantly affecting healthy cells.

It is believed that many systemic herbicides alone or in combination with other herbicides and fungicides will slow this beneficial anti-tumor effect.

The mixture of (1) the N-phosphonoglycines and (2) N-chlorophenyl-carbamates and N-chlorophenylthiocarbamates are also effective against viruses including rhinovirus, HIV, herpes, and influenza.


## WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating viral infections and inhibiting the growth or tumors or cancers comprising a safe and effective amount of a mixture of (1) N-chlorophenylcarbamates and N-chlorophenylthiocarbamates of the formula:



wherein n is from 1 to 3; X is selected from the group consisting oxygen and sulfur and wherein R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms and the pharmaceutically acceptable salts of these compounds; and

- (2) N-phosphonoglycine of the formula:



wherein X is selected from the group consisting of hydroxy, alkoxy or chloroxy up to 12 carbon atoms; lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidiny, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline.

2. A pharmaceutical composition according to Claim 1 comprising a pharmaceutically acceptable carrier and a safe and effective amount of N-phosphonoglycine derivatives and N-chlorophenylcarbamates and N-chlorophenylthiocarbamates.
3. A pharmaceutical composition according to Claim 1 or 2 wherein said pharmaceutical acceptable acid addition salts are selected from the group consisting of hydrochloride, acetate, salicylate and mixtures thereof.

4. A method of treating cancer in warm blooded mammals comprising administering a safe and effective amount of a pharmaceutical composition according to Claim 1, 2 or 3.
5. A method according to Claim 4 wherein from 2 mg/kg body weight to 400 mg/kg of said mixture is administered orally or enterically, intravenously, parenterally or by injection into or around the tumor site.
6. A method according to Claim 4 or 5 wherein said mixture is administered in a solid form and wherein said solid form includes a carrier selected from the group consisting of lactose, sucrose, gelatin and agar.
7. A method according to Claim 4 or 5 wherein said mixture is administered in a liquid form and wherein said liquid dosage form is selected from the group consisting of aqueous solutions, emulsions, suspension solutions, and suspensions reconstituted from non-effervescent and effervescent preparations.
8. A unit dosage composition for treating cancer, tumors and viral infections comprising a safe and effective amount of a pharmaceutical composition to Claim 1, 2 or 3.
9. A unit dosage composition according to Claim 8 wherein said carbamate is chloroprofam.
10. A method of treating viral infections in warm blooded mammals comprising administering a safe and effective amount of a pharmaceutical composition according to Claim 1, 2 or 3.
11. A method of treatment according to Claim 10 wherein said mixture is administered orally or enterically, intravenously, parenterally or by injection into and around said tumor.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/04953

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/27 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CANCER RES., vol. 41, no. 5, 1981, pages 1879-83, XP000579495 ZILKAH ET AL.: "Effect of inhibitors of plant cell division on mammalian tumor cells in vitro" see page 1879 see page 1880, right-hand column, line 11 - line 15 see page 1882, left-hand column, line 13 - right-hand column, line 7 see page 1883, left-hand column, last line - right-hand column, line 5 --- -/--</p>	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

21 August 1996

Date of mailing of the international search report

05.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Gerli, P

# INTERNATIONAL SEARCH REPORT

International Application No  
PLT/US 96/04953

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROC.AM.ASSOC.CANCER RES., vol. 22, 1981, page 270 XP002011350 ZILKAH ET AL.: "The effect of plant mitotic inhibitors on mammalian tumor cells" see abstract no.1072 ---</p>	1-11
A	<p>DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL DIALOG information services; abstract no. 212600, XP002011351 see abstract &amp; J.CELL BIOL., vol. 61, no. 2, 1974, pages 514-36, BROWN ET AL.: "Microtubule biogenesis and cell shape in Ochromonas. III. Effects of the herbicidal mitotic inhibitor isopropyl N phenylcarbamate on shape and flagellum regeneration" ---</p>	1-11
A	<p>ARCH.IMMUNOL.THER.EXP., vol. 33, no. 219, 1985, pages 325-9, XP000579382 DUS ET AL: "Cytostatic activity in vitro of phosphonic acid derivatives" see page 325, table 1, compound no. 4 see page 328, line 25 - line 30 ---</p>	1-11
A	<p>PHARM.CHEM.J., vol. 12, 1978, pages 1428-1431, XP000579394 BANDURINA ET AL.: "Synthesis and antitumor activity of aminophosphonic acids" see page 1428, paragraph 1 see page 1429, paragraph 1 see page 1430; table 2 ---</p>	1-11
A	<p>TROP.AGRIC.RES.SER., vol. 19, 1985, pages 195-208, XP000579507 MOCHIDA ET AL.: "Chemical control of green leafhoppers to prevent virus diseases, especially tungro disease, on susceptible intermediate rice cultivars in the tropics" see page 206; table 7 ---</p>	1-11
A	<p>US,A,5 114 951 (KING) 19 May 1992 cited in the application see claim 1 -----</p>	1-11



# INTERNATIONAL SEARCH REPORT

International application No.

PCI/US96/04953

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 4-7,10-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

